Aptar’s UDS Powder system enters ENA Respiratory’s POSITS Phase II trial. Analyse what INNA-051 must prove in 2026 and why the device choice matters. Read more.
Aptar Pharma and COVIRIX Medical announce a DPI feasibility collaboration for inhaled broad-spectrum antivirals. Read the analysis.
Kenox Pharmaceuticals announces clinical manufacturing readiness for inhaled and nasal drug products. What this means for OINDP development timelines and IVBE strategy.
Kinaset raises $103M to advance frevecitinib, a novel inhaled JAK inhibitor for severe asthma. Find out what makes this candidate different.